Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of a novel potent melanin-concentrating hormone receptor 1 antagonist, AZD1979, on body weight homeostasis in mice and dogs.
Ploj K, Benthem L, Kakol-Palm D, Gennemark P, Andersson L, Bjursell M, Börjesson J, Kärrberg L, Månsson M, Antonsson M, Johansson A, Iverson S, Carlsson B, Turnbull A, Lindén D. Ploj K, et al. Among authors: gennemark p. Br J Pharmacol. 2016 Sep;173(18):2739-51. doi: 10.1111/bph.13548. Epub 2016 Aug 3. Br J Pharmacol. 2016. PMID: 27400775 Free PMC article.
A modeling approach for compounds affecting body composition.
Gennemark P, Jansson-Löfmark R, Hyberg G, Wigstrand M, Kakol-Palm D, Håkansson P, Hovdal D, Brodin P, Fritsch-Fredin M, Antonsson M, Ploj K, Gabrielsson J. Gennemark P, et al. J Pharmacokinet Pharmacodyn. 2013 Dec;40(6):651-67. doi: 10.1007/s10928-013-9337-x. Epub 2013 Oct 25. J Pharmacokinet Pharmacodyn. 2013. PMID: 24158456
Discovery of (3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a Melanin Concentrating Hormone Receptor 1 (MCHr1) Antagonist with Favorable Physicochemical Properties.
Johansson A, Löfberg C, Antonsson M, von Unge S, Hayes MA, Judkins R, Ploj K, Benthem L, Lindén D, Brodin P, Wennerberg M, Fredenwall M, Li L, Persson J, Bergman R, Pettersen A, Gennemark P, Hogner A. Johansson A, et al. Among authors: gennemark p. J Med Chem. 2016 Mar 24;59(6):2497-511. doi: 10.1021/acs.jmedchem.5b01654. Epub 2016 Feb 5. J Med Chem. 2016. PMID: 26741166
An oral antisense oligonucleotide for PCSK9 inhibition.
Gennemark P, Walter K, Clemmensen N, Rekić D, Nilsson CAM, Knöchel J, Hölttä M, Wernevik L, Rosengren B, Kakol-Palm D, Wang Y, Yu RZ, Geary RS, Riney SJ, Monia BP, Isaksson R, Jansson-Löfmark R, Rocha CSJ, Lindén D, Hurt-Camejo E, Crooke R, Tillman L, Rydén-Bergsten T, Carlsson B, Andersson U, Elebring M, Tivesten A, Davies N. Gennemark P, et al. Sci Transl Med. 2021 May 12;13(593):eabe9117. doi: 10.1126/scitranslmed.abe9117. Sci Transl Med. 2021. PMID: 33980578
A case-study of model-informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II.
Knöchel J, Nilsson C, Carlsson B, Wernevik L, Hofherr A, Gennemark P, Jansson-Löfmark R, Isaksson R, Rydén-Bergsten T, Hamrén B, Rekić D. Knöchel J, et al. Among authors: gennemark p. CPT Pharmacometrics Syst Pharmacol. 2022 Dec;11(12):1569-1577. doi: 10.1002/psp4.12866. Epub 2022 Oct 1. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 36126230 Free PMC article. Clinical Trial.
49 results